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Aim. Enlarged cervical lymph nodes (LNs) in patients with thyroid cancer are usually assessed by ﬁne-needle aspiration cytology
(FNAC). Thyroglobulin (Tg) is frequently elevated in malignant FNAC needle wash specimens (FNAC-Tg). The objectives of
the study were to (1) determine an appropriate diagnostic cut-oﬀ for FNAC-Tg levels (2) compare FNAC and FNAC-Tg results
in a group of 108 patients aﬀected by diﬀerentiated thyroid carcinoma (DTC). Methods. A total of 126 consecutive FNACs were
performed on enlarged LNs and the ﬁnal diagnosis was conﬁrmed by surgical pathology examination or clinical follow-up. The
best FNAC-Tg cut-oﬀ level was selected by receiver operating curve analysis, and diagnostic performances of FNAC and FNAC-Tg
were compared. Results. The rate of FNAC samples adequate for cytological examination was 77% in contrast FNAC-Tg available
in 100% of aspirates (P<. 01). The sensitivity, speciﬁcity, and accuracy of FNAC were 71%, 80%, 74%, 100%, 80%, and 94%,
respectively. The most appropriate cut-oﬀ value for the diagnosis of thyroid cancer metastatic LN was 1.1ng/mL (sensitivity 100%,
speciﬁcity 100%). Conclusions. The diagnostic performance of needle washout FNAC-Tg measurement with a cut-oﬀ of 1.1ng/mL
compared favorably with cytology in detecting DTC node metastases.
1.Introduction
The prognosis of patients who receive appropriate treatment
for thyroid carcinoma is usually favourable, especially for
diﬀerentiated thyroid carcinoma (DTC). However, although
most patients have a long-term survival rate, 5% to 20%
of patients will develop recurrence during the followup,
primarily in the cervical lymph nodes (LNs) [1, 2]. These
LNs metastases may be detected clinically, but now are
most often discovered on ultrasonography (US) [3]. It is
of great importance to diﬀerentiate accurately LN metas-
tases from benign reactive lymph nodes in order to avoid
unnecessary treatment, but also to treat metastatic patients
without delay. As consequence, diagnostic procedures must
oﬀer good sensitivity, but also high negative predictive
value. US criteria distinguishing benign from metastatic or
suspicious LNs have been described but they lack accuracy
[4]. US-guided ﬁne needle cytology (FNAC) proved to be
a reliable method in examining the neck in patients who
were previously treated for thyroid cancer [5, 6]. However,
sensitivity of FNAC is far from excellent, varying from
75% to 85%, and altered by high rate of nondiagnostic or
false-negative samples. To improve the diagnostic yield of
FNAC, several authors have proposed measurement of Tg
in aspirates (FNAC-Tg), particularly in the cases involving
small, partially cystic, lymph nodes [7–12]. On the basis of
prior studies, an increased Tg level in the needle washout
has been shown to directly reﬂect the status of metastatic
lymph nodes in patients aﬀected by diﬀerentiated thyroid
carcinoma. However, controversies still persist concerning
some issues. First, there are few studies to validate the beneﬁt
of FNAC-Tg over FNAC alone, and, second, cut-oﬀ values
rangingfrom0.9to39ng/mLhavebeensuggestedforFNAC-
Tg, depending on the method used for the measurement
[7, 13–15]. As consequence, the exact place for FNAC-
Tg in the management of DTC patients is still debated.2 Journal of Thyroid Research
Thisstudywasthenundertakento(1)determineadiagnostic
cut-oﬀ value for washout Tg in patients treated by total
thyroidectomy for detecting recurrences, and (2) to compare
the performance of the Tg cut-oﬀ value to US-guided FNAC
for detecting DTC recurrences.
2.MaterialsandMethods
Our institutional review board approved our research study,
and all subjects gave written informed consent.
2.1. Patients. Between January 2006 and February 2009 a
t o t a lo f1 2 6c o n s e c u t i v eU S - g u i d e dF N A C sw e r ep e r f o r m e d
on enlarged LNs. The samples were obtained from 108
patients (19 males, 89 females; age 42.7 ± 18.2 years; 91
patients with 1, 94 with 2, and 5 with 3 lesions, resp.).
All patients had histologically conﬁrmed primary DTC
(papillary, n = 99, including two tall-cell variants; follicular,
n = 9, including 2 H¨ urtle cells carcinomas). The primitive
carcinomawasclassiﬁedpT1in34cases,pT2in43cases,pT3
in 24 cases, and pT4 in 7 cases. Forty-ﬁve patients (42%) had
LN metastases at diagnosis. All patients underwent (near)
total thyroidectomy and subsequent radioiodine ablation
(administered activity from 1.85 to 3.70GBq). The US
criteria for possible malignant inﬁltration of lymph nodes
were rounded contour, irregular internal echogenicity, punc-
tate calciﬁcations, ﬂuids components, and abnormal colour
Doppler pattern. Patients with positive cytology and/or
FNAC-Tg measurement (n = 86, 96 lesions) underwent
surgeryand,ifnecessary,furtherradioiodinetreatments.The
diagnosis was conﬁrmed in all cases by surgical pathology
examination. Patients with negative FNAC-Tg measurement
and cytology (n = 22, 30 lesions) underwent further follow
up by serial clinical examinations, serum Tg measurements,
neck US, and, whenever necessary, additional imaging
procedures(i.e.,radioiodinescan, 18FDG-PET/CT).NoDTC
recurrence was detected among these patients (follow up:
mean 36 months, range 15–42 months).
2.2. US-Guided FNAC Procedure. All US-guided FNAC pro-
cedures were performed on supine patients with the neck
hyperextended under continuous real-time US guidance
withahigh-resolutiontransducer(ACUSON ×150,Siemens,
Erlangen, Germany). Each lesion was aspirated at least twice
by a 21G needle. The needle was inserted obliquely within
the transducer plane of view, and moved back and forth
through the nodule to compensate for patient movement
and needle deﬂection. Gradual aspiration was applied by a
20mL syringe connected to Cameco’s device. Contents of
needles were expelled onto glass slides and smeared with
a second slide to spread ﬂuid across the surface. Slides
were ﬁxed in 95% ethanol, papanicolaou stained to identify
cellular details, and read by our cytopathologist. Following
collection of cytology samples the needles were washed
by 1mL of normal saline in a plain serum tube (Vacu-
tainer Systems, Plymouth, UK) and the washout directly
sent to the laboratory [16]. Cytological examinations were
performed by experienced cytopathologists and expressed
as (1) positive: presence of epithelial cells with atypical
cytological characteristics, or with cytological features of
papillarycarcinoma;(2)negative:reactivelymphadenitisand
absence of malignant cells; (3) inadequate or nondiagnostic:
absence of cells or presence of blood cells.
2.3. Tg Measurement. Thyroglobulin was measured in ﬁne-
needlewashoutsusinganimmunoradiometricassay(IRMA)
based on coated tubes with monoclonal antibodies directed
against distinct epitopes of the molecule of Tg (DYNO
test Tg-plus, BRAHMS Diagnostic GmbH, Berlin, Ger-
many). With this measurement, analytic sensitivity, deﬁned
as the detectable minimum concentration diﬀerent from
zero (mean value + 2 standard deviation), and functional
sensitivity, deﬁned as the lowest value that was measured
with the precision of a maximum 20% interassay variance,
were 0.08ng/mL and 0.2ng/mL, respectively. We did not
measure Tg antibodies (FNAC-TgAb) because the clinical
performance of FNAC-Tg is unaﬀected by serum TgAb [17].
2.4. Data Analysis. Diagnostic performance (i.e., sensitiv-
ity, speciﬁcity, positive predictive value, negative predictive
value, and accuracy) of FNAC and FNAC-Tg was evaluated
by comparing the results of the two procedures to the status
of the patients deﬁned as follows: malignant lymph node
from thyroid cancer was proved by histological examination
of surgically resected LNs; benign lymph node was proved
by negative histological examination of surgically respected
LNs, or if disappearance or absence of evolution on imaging
modalities was demonstrated at 12 months or more follow
up.
The Chi-square (χ2) test, performed with SAS version 9.1
for Windows (SAS Institute, Cary, NC, US) was employed
to compare the diagnostic rate of FNAC and FNAC-Tg.
The FNAC-Tg receiver operating characteristic curve was
developed using MedCalc 6.1 software (MedCalc Software,
Mariakerke, Belgium). The cut-oﬀ values which maximise
the sum of sensitivity plus speciﬁcity were determined as the
points in the upper left hand corner. A P value <. 05 was
considered to indicate statistical signiﬁcance.
3. Results
Patients characteristics and cytological, pathological, and
biochemical data are displayed in Table 1. Of the 126
lymph node lesions assessed for postoperative recurrences
by US-guided FNAC and FNAC-Tg, 86 (68%) lesions were
ﬁnally diagnosed as malignant and the remaining 40 (32%)
lesions were diagnosed as benign LNs, respectively. The
ﬁnal diagnosis of the 86 malignant and 8 benign LN was
established by surgical pathology; the remaining 32 benign
lesions were diagnosed based on imaging follow up after at
least 1 year. The time from thyroid ablation to US-FNAC
was 19.5 ± 14.31 and 19.4 ± 13.76 months in patients with
benign and malignant lesions, respectively (P not signiﬁ-
cant).SerumTglevelswerehigherinpatientswithmalignant
lesions (median 4.20ng/mL, range <0.2–27.10ng/mL) than
those with benign lesions (median .80ng/mL, range <0.2–
2.70ng/mL; P<. 0001). Serum TgAb were positive in 11Journal of Thyroid Research 3
Table 1: Patients characteristics and cytological, pathological, and biochemical data.
Patients Histology pTNM Duration
(months)
Tg
(ng/mL)
TgAb
(IU/mL) Lesions Sites
FNA Final
diagnosis
Cytology Tg
(ng/mL)
1 PTC pT1N1Mx 6 1.0 <60 1 R II ND <0.2 B
2 PTC pT1NxMx 15 4.6 <60 1 L III Negative 435.2 M
3 PTC pT1NxMx 18 1.7 <60 1 R IV CTM 85.3 M
4 PTC pT1NxMx 30 0.4 <60 1 R III ND <0.2 B
5 PTC pT1N0Mx 6 3.1 <60 1 L II ND 97.2 M
6 PTC pT2N0Mx 19 9.1 <60 2 R IV, VI CTM 118.5 M
7 PTC pT2NxMx 47 <0.2 334 1 L IV CTM 879.4 M
8 PTC pT2N1Mx 6 0.9 78 1 VI Negative 1.1 B
9 PTC pT1N1Mx 9 9.8 <60 1 L II ND 1348.6 M
10 PTC pT2N0Mx 14 1.5 <60 1 L III CTM 358.5 M
11 PTC pT1NxMx 8 12.6 <60 3 R II CTM 2387.4 M
12 PTC pT2NxMx 16 9.7 <60 1 R III CTM 875.9 M
13 PTC pT1NxMx 9 6.3 <60 1 R II CTM 958.6 M
14 PTC pT1N0Mx 11 1.0 <60 1 L III Negative 48.7 M
15 PTC pT2N1Mx 39 9.5 <60 1 L IV CTM >3000 M
16 PTC pT1NxMx 12 0.8 <60 1 L III CTM 107.5 M
17 PTC pT2NxMx 19 2.7 <60 3 R III-IV ND, CTM 541.6 RIII B, IV
M
18 PTC pT4N1Mx 6 1.6 <60 1 L III CTM 31.8 M
19 PTC pT1N1Mx 15 0.5 289 1 R IV ND <0.2 B
20 PTC pT2N1Mx 3 2.3 <60 1 L III ND 540.7 M
21 PTC pT1NxMx 34 4.1 <60 1 L III CTM 650.6 M
22 PTC pT2N1Mx 8 <0.2 98 1 L II ND 5.8 M
23 PTC pT1NxMx 9 0.8 <60 2 R II, R III CTM 87.5 M
24 PTC pT4N0Mx 10 1.4 755 1 R II CTM 196.4 M
25 PTC pT2NxMx 21 11 <60 1 R III ND 585.3 M
26 PTC pT1NxMx 9 <0.2 <60 1 R III Negative <0.2 B
27 PTC pT4N1M 12 1.1 160 1 L III Negative 0.3 B
28 PTC pT1N0Mx 23 5.3 <60 1 R III CTM 784.2 M
29 PTC pT2N1Mx 5 <0.2 >1000 1 R III ND <0.2 B
30 PTC pT2N0Mx 22 4.9 <60 1 R III CTM 641.5 M
31 PTC pT1NxMx 36 0.3 367 1 R IV Negative <0.2 B
32 PTC pT1NxMx 15 7.1 <60 1 R III ND 665.4 M
33 PTC pT2N0Mx 41 <0.2 <60 1 L II Negative <0.2 B
34 PTC pT1NxMx 24 2.6 <60 1 R III CTM 570.6 M
35 PTC pT4N0Mx 31 1.4 >1000 3 L IV, VI CTM 96.7 M
36 PTC pT4N1M 12 27.1 <60 1 R II CTM 2987.3 M
37 PTC pT1N1Mx 54 6.8 <60 1 L III CTM 875.6 M
38 PTC pT2NxMx 12 <0.2 149 1 R IV Negative <0.2 B
39 PTC pT2N0Mx 9 0.9 <60 1 R II Negative <0.2 B
40 PTC pT1N0Mx 34 2.4 89 1 L III ND 347.4 M
41 PTC pT2NxMx 14 5.1 <60 1 L IV ND 1655.7 M
42 PTC pT4N1M 8 7.7 <60 1 L III Negative 2076.5 M
43 PTC pT1NxMx 61 1.1 <60 1 VI Negative <0.2 B
44 PTC pT2N0Mx 22 1.0 <60 1 L II CTM 90.6 M4 Journal of Thyroid Research
Table 1: Continued.
Patients Histology pTNM Duration
(months)
Tg
(ng/mL)
TgAb
(IU/mL) Lesions Sites
FNA Final
diagnosis
Cytology Tg
(ng/mL)
45 PTC pT2N1Mx 12 6.4 <60 2 R III-IV CTM, ND 458.6 RIII M, IV
B
46 PTC pT1NxMx 45 0.6 <60 1 R IV Negative <0.2 B
47 PTC pT4N0Mx 36 4.3 <60 1 R III CTM 766.4 M
48 PTC pT2NxMx 11 1.9 <60 1 L II ND 306.5 M
49 PTC pT3NxMx 18 7.0 <60 1 R III CTM 955.6 M
50 PTC pT2NxMx 10 1.2 <60 1 L III Negative <0.2 B
51 PTC pT1N1Mx 12 3.9 <60 1 R III CTM 564.7 M
52 PTC pT3N0Mx 25 6.4 190 1 R III ND 1078.6 M
53 PTC pT2N1Mx 16 9.5 <60 1 L IV CTM 759.4 M
54 PTC pT1NxMx 9 0.6 <60 1 R III Negative <0.2 B
55 PTC pT3N1Mx 60 <0.2 107 2 L II-III CTM 137.5 M
56 PTC pT1N0Mx 11 5.3 <60 1 R II CTM 654.8 M
57 PTC pT2N1Mx 18 1.1 860 1 L III ND <0.2 B
58 PTC pT1NxMx 9 0.9 <60 1 R IV Negative <0.2 B
59 PTC pT2NxMx 28 1.1 <60 1 R III ND 99.6 M
60 PTC-TCV pT3NxMx 13 4.6 <60 1 L II CTM 436.8 M
61 PTC pT1NxMx 2 2.7 <60 1 R II CTM 194.5 M
62 PTC pT3NxMx 7 21.9 <60 3 R III, L II Neg.,
CTM >3000 RIII B, LII
M
63 PTC pT1NxMx 18 1.1 <60 1 R III CTM 27.4 M
64 PTC pT3NxMx 10 3.5 <60 1 VI CTM 147.4 M
65 PTC pT2N0Mx 29 <0.2 >1000 1 R IV Negative <0.2 B
66 PTC pT3N1Mx 6 5.6 <60 1 L III CTM <0.2 M
67 PTC pT1N1Mx 11 2.1 <60 1 R III ND <0.2 M
68 PTC pT3N0Mx 18 0.7 <60 1 R III ND <0.2 B
69 PTC pT2N0Mx 23 1.7 <60 1 L IV CTM 75.6 M
70 PTC pT1NxMx 9 3.5 <60 1 L II ND 72.6 M
71 PTC pT3N0Mx 18 7.1 <60 2 R IV, VI CTM 386.2 RIV B, VI
M
72 PTC pT1NxMx 7 1.8 1 L II Negative <0.2 B
73 PTC pT2NxMx 11 3.6 <60 1 R III ND 245.7 M
74 PTC pT2NxMx 29 2.2 <60 2 L III-IV CTM 67.4 IV M, III B
75 PTC pT2N1Mx 14 5.7 <60 1 L II CTM 198.7 M
76 PTC pT1N0Mx 8 1.5 <60 1 R IV CTM 26.1 M
77 PTC pT2NxMx 10 2.1 <60 1 VI CTM 59.7 M
78 PTC pT1NxMx 18 0.7 <60 1 R IV Negative <0.2 B
79 PTC pT3N1Mx 34 12.3 <60 1 R III ND 678.4 M
80 PTC pT1N1Mx 16 1.8 <60 1 L II Negative <0.2 B
81 PTC pT2N0Mx 52 0.9 <60 1 R III Negative <0.2 B
82 PTC pT2N1Mx 25 9.4 <60 1 L III ND 563.6 M
83 PTC pT1NxMx 9 4.1 <60 1 VI CTM 64.7 M
84 PTC pT2N1Mx 18 3.1 <60 1 R IV CTM 116.4 M
85 PTC-TCV pT2NxMx 20 15.5 <60 3 R IV-L III CTM 432.9 M
86 PTC pT3N0Mx 8 <0.2 56 1 VI ND <0.2 B
87 PTC pT1N0Mx 31 2.9 <60 1 R IV CTM 39.3 M
88 PTC pT2NxMx 11 1.7 <60 1 R III Negative <0.2 B
89 PTC pT2NxMx 54 6.5 <60 1 L IV ND 467.7 M
90 PTC pT1N1Mx 28 0.3 651 1 R II Negative <0.2 B
91 PTC pT2NxMx 12 2.1 <60 1 L III CTM 88.6 MJournal of Thyroid Research 5
Table 1: Continued.
Patients Histology pTNM Duration
(months)
Tg
(ng/mL)
TgAb
(IU/mL) Lesions Sites
FNA Final
diagnosis
Cytology Tg
(ng/mL)
92 PTC pT3N0Mx 17 9.4 <60 2 R IV, VI CTM 156.2 IV M, VI B
93 PTC pT1NxMx 22 1.0 <60 1 L IV Negative <0.2 B
94 PTC pT2N1Mx 9 4.3 <60 1 VI Negative 53.8 M
95 PTC pT2N0Mx 26 <0.2 <60 1 R IV Negative <0.2 B
96 PTC pT1N0Mx 12 0.9 <60 1 R III ND 2.7 M
97 PTC pT2NxMx 17 8.1 <60 1 L II ND 356.4 M
98 PTC pT2NxMx 9 0.9 <60 1 R III CTM 19.6 M
99 PTC pT3N1Mx 12 1.1 <60 1 L III ND 0.6 B
100 FTC pT1N1Mx 45 4.9 <60 1 R III CTM 117.5 M
101 FTC pT3N0Mx 36 1.4 <60 1 R III Negative <0.2 B
102 FTC pT2N1Mx 11 <0.2 >1000 2 R III-IV Negative <0.2 B
103 FTC (HC) pT1NxMx 72 10.4 <60 1 R IV ND 278.9 M
104 FTC pT2N1Mx 11 0.7 <60 1 R III Negative <0.2 B
105 FTC pT1N0Mx 18 2.1 <60 1 R IV CTM 74.4 M
106 FTC (HC) pT1N0Mx 6 1.9 <60 1 L III Negative 0.8 B
107 FTC pT2N1Mx 25 7.8 <60 1 R II ND 116.4 M
108 FTC pT1NxMx 19 4.6 <60 2 L II-III CTM 89.5 M
FNA, ﬁne-needle aspiration; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; TCV, tall-cell variant; HC H¨ urtle cell; R, right, L, left;
duration, time from thyroid ablation to FNA; II-III-IV, upper, middle, lower neck lateral compartment, IV, central neck compartment.
Table 2:DiagnosticperformanceofFNACcytologyascomparedto
ﬁnal diagnosis.
Final diagnosis
FNAC Malignant LNs
(n = 86)
Benign LNs
(n = 40)
Positive 61 0
Negative 4 32
Inadequate 21 8
Table 3: Diagnostic performance of FNAC-Tg as compared to ﬁnal
diagnosis.
Malignant
LNs (n = 86)
Benign LNs
(n = 40)
FNAC-Tg >1.1ng/mL 86 0
FNAC-Tg ≤1.1ng/mL 0 40
Table 4: Figures of merits of FNAC cytology and FNAC Tg.
FNAC Sensitivity Speciﬁcity PPV NPV Accuracy
Cytology 71% 80% 88% 56% 74%
Tg 100% 100% 100% 100% 100%
of 40 patients with benign lesions and 7 of 67 patients
with malignant lesions (P<. 001). The rate of FNAC
samples adequate for cytological examination was 77% (97
samples) in contrast FNAC-Tg available in 100% of aspirates
(P<. 01). As shown in Table 2 cytological examination
correctly identiﬁed 61 malignant LNs, was negative in 4, and
Table 5: Rate of positive FNAC-Tg values (i.e., >1.1ng/mL) in
patients with inadequate or misdiagnosed FNAC-cytology.
Final status FNAC inadequate
(n = 29)
FNAC
false-negative
(n = 4)
Malignant LNs
(n = 25) 21/21 4/4
Benign LNs
(n = 8) 0/8 —
inadequate in 21. For benign LNs, FNAC was negative in
32 and inadequate in 8. It showed no false-positive results.
Thus, sensitivity, speciﬁcity, positive predictive value (PPV),
negative predictive value (NPV), and accuracy of FNAC
were 71%, 80%, 88%, 56%, and 74%, respectively. The
ROC curve analysis demonstrated that the most appropriate
cut-oﬀ value for the diagnosis of thyroid cancer metastatic
lesions was 1.1ng/mL (sensitivity 100%, speciﬁcity 100%,
PPV 100%, NPV 100%, accuracy 100%; Figure 1, Tables 3,
and 4). Basing on this cut-oﬀ level, the FNAC-Tg results
correctly concluded all 25 malignant (100%) and 8 benign
(100%) cases with false-negative (n = 4) and nondiagnostic
(n = 29) FNAC results, respectively (Table 5). The FNAC-
Tg levels were signiﬁcantly higher in malignant (median
513.8ng/mL, range 1.7-> 3000ng/mL) than benign (median
<0.2ng/mL,range<0.2–1.1ng/mL)lesions,respectively(P<
.0000001).Particularly,specimenTglevelswereundetectable
(i.e., <0.2ng/mL) in 36 cases and were 0.3, 0.6, 0.8, and
1.1ng/mL in remaining 4 cases with benign lesions.6 Journal of Thyroid Research
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Figure 1: FNAC-Tg: ROC curve analysis.
4. Discussion
An accurate discrimination between metastatic and reactive
LNs is essential in the management of thyroid cancer.
Cytological examination of FNAC samples disclosed by
US has been the most accurate method to diagnose a
cervical LN. However, as showed also in our study, its
sensitivityisnegativelyimpactedbytherateofnondiagnostic
samples although FNAC procedures are performed by US-
experienced physicians and dedicated cytopathologists [5, 6,
15].Inthepresentstudy23%ofsampleswerenondiagnostic;
this perfectly conforms with previously reported data [18].
Cystic metastasis and partial LN involvement comprise most
of the inadequate/nondiagnostic FNAC-cytology cases and
could be misinterpreted as a benign cervical cystic mass or
branchial cleft cysts and could therefore delay the correct
diagnosis and a further radical neck lymphadenectomy.
The immunocytochemical Tg staining on FNAC samples
from of neck nodes was previously evaluated in patients
with DTC. Because an adequate FNAC sample is required,
however, the practical impact of this technique is limited in
clinical practice [19]. Recently, the FNAC-Tg measurement
has been proposed to be a useful diagnostic technique in
the management of patients with thyroid cancer. Because
Tg is produced only by follicular thyrocyte-derived cells,
measurement of Tg in FNAC specimens of nonthyroidal
tissues enables the detection of persistence, recurrence, or
metastasis of diﬀerentiated thyroid carcinoma. In our study
FNAC-Tganalysiswasmoresensitivefordetectingmetastasis
when compared with FNAC alone, and allows the accurate
diagnosis in samples with inconclusive cytology. Our results
perfectly conforms those recently reported by Bournaud and
colleagues [18]. By contrast Tg could be determined in all
aspirates and a sensitivity of 100% was achieved in our
series, that is at the higher end of previously reported data
(81%–100%) [7, 9, 14, 17, 18]. Although the performance of
FNAC-Tg is well established, the Tg threshold value remains
controversial. The Tg assays employed and methods for
determining the cut-oﬀ value diﬀered from one study to
another, resulting in a large range, from 0.9ng/mL to values
as high as 39ng/mL, proposed in the literature.
In our study the best Tg threshold was determined at
1.1ng/mL by ROC curve analysis. Using a threshold of
1.1ng/mL we observe neither false-positive results in non-
malignant LNs nor false-negative results in malignant LNs
at ﬁnal diagnosis. Additionally, FNAC-Tg results correctly
classiﬁed as malignant 4 lesions that tested negatively
in cytological examination. All in all, our results are in
accordance with those of Snozek and colleagues that used
a Tg assay with a functional sensitivity at 0.1ng/mL and
proposed a cut-oﬀ level of 1.00ng/mL: basing on their
results these authors suggested that FNAC-Tg should be
substituted for FNAC in many cases [7]. Of importance, our
samples were obtained in a population of well-diﬀerentiated
thyroidcarcinomas(i.e.,onlytwoH¨ urtlecellandtwotall-cell
variants among 108 DTC cases). Several authors reported,
however, that FNAC-Tg levels could be undetectable in
some types of thyroid cancers (i.e., poorly diﬀerentiated
thyroid carcinomas) [13, 17]. This correspond to the fact
that amount and intensity of Tg expression parallel with
diﬀerentiationofthetumorandcouldproducefalse-negative
results. As a consequence, caution is needed, and a combi-
nation of FNAC and FNAC-Tg should remain the standard,
especially in patients harboring less diﬀerentiated thyroid
carcinomas.
5. Conclusions
The diagnostic performance of needle washout FNAC-
Tg measurement with a cut-oﬀ of 1.1ng/mL compared
favourably with cytology and allowed accurate diagnosis in
all cases in whom cytology was nondiagnostic.
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